Scarica l'app Stockscreener
1.6806
5.87%
-0.1094
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IOVA Giù?
Forum
Previsione
Frazionamento azionario
Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie
Shareholder Rights Advocates at Levi & Korsinsky Investigate Iovance Biotherapeutics, Inc. (IOVA) Regarding Possible Securities Fraud Violations - ACCESS Newswire
IOVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. ... - Eagle-Tribune
IOVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Kaplan Fox Announces an Investigation Into Iovance Biotherapeutics, Inc. (IOVA) for Potential Securities Law Violations - FinancialContent
Why Iovance Biotherapeutics (IOVA) Is Among the Best Low Priced Biotech Stocks to Buy Now - Insider Monkey
News Flash: 12 Analysts Think Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Earnings Are Under Threat - simplywall.st
Need To Know: Analysts Just Made A Substantial Cut To Their Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Estimates - Yahoo Finance
Iovance Biotherapeutics Stock (IOVA): Navigating Turbulent Times - Value The Markets
Kirby McInerney LLP Announces Investigation of Claims - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Iovance Biotherapeutics, Inc. (IOVA) Investors to Inquire about Securities Investigation - ACCESS Newswire
Iovance revises 2025 revenue guidance to $250M-$300M amid ATC expansion - MSN
Securities Fraud Investigation Into Iovance Biotherapeutics, Inc. (IOVA) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm - Benzinga
Iovance Biotherapeutics (IOVA) Price Target Lowered by Goldman S - GuruFocus
Iovance Biotherapeutics (IOVA) Price Target Lowered by Mizuho | IOVA Stock News - GuruFocus
Iovance Biotherapeutics (IOVA) Target Price Lowered by Barclays | IOVA Stock News - GuruFocus
Iovance falls after guidance cut, revenue miss - MSN
Iovance Biotherapeutics (IOVA) Price Target Slashed by Mizuho | - GuruFocus
10 Best Low-Priced Biotech Stocks to Buy Now - Insider Monkey
Iovance Biotherapeutics’ (IOVA) Annual Maintenance: - GlobeNewswire
Iovance Biotherapeutics’ (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% – Hagens Berman - TradingView
Truist Downgrades Iovance Biotherapeutics to Hold From Buy, After Q1 Sales Miss, Guidance Cut - marketscreener.com
Iovance Biotherapeutics (IOVA) Faces Price Target Downgrade by B - GuruFocus
Iovance Biotherapeutics (IOVA) Downgraded by Truist Amid Revenue Concerns | IOVA Stock News - GuruFocus
Iovance Biotherapeutics: Abysmal Q1 2025 Performance Creates Buying Opportunity - Seeking Alpha
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2025 Earnings Call Transcript - Insider Monkey
Market Today: Trade Desk Surges on Strong Earnings; Iovance Biotherapeutics Plummets - GuruFocus
JMP Securities Downgrades Iovance Biotherapeutics (BIT:1IOVA) - Nasdaq
Iovance Biotherapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Iovance Biotherapeutics (IOVA) Downgraded by JMP Securities | IO - GuruFocus
Iovance Biotherapeutics (IOVA) Stock Rating Maintained, Price Ta - GuruFocus
JMP Securities Downgrades Iovance Biotherapeutics (LSE:0JDK) - Nasdaq
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - Business Wire
Securities Fraud Investigation Into Iovance Biotherapeutics, Inc. (IOVA) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Business Wire
Iovance Biotherapeutics (IOVA) Shares Plummet on Revenue Miss an - GuruFocus
Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi - Endpoints News
Iovance Biotherapeutics (IOVA) Shares Plummet on Revenue Miss and Forecast Cut - GuruFocus
Iovance stock falls after guidance cut, Q1 miss (IOVA:NASDAQ) - Seeking Alpha
Why Iovance Biotherapeutics Stock Is Crashing Today - AOL.com
Iovance Biotherapeutics (IOVA) Downgraded by JMP Securities | IOVA Stock News - GuruFocus
Iovance Stock Sinks 46%. Here’s Why the Biotech Is Tumbling. - Barron's
Why Iovance (IOVA) Stock Is Plummeting Today - GuruFocus
Iovance Biotherapeutics (IOVA) Price Target Cut by TD Cowen | IOVA Stock News - GuruFocus
Expert Outlook: Iovance Biotherapeutics Through The Eyes Of 9 Analysts - Benzinga
Iovance Biotherapeutics (IOVA) Downgraded Amid Concerns Over Lau - GuruFocus
No Excuses, Iovance Biotherapeutics' Amtagvi Launch Has Underperformed (NASDAQ:IOVA) - Seeking Alpha
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% On '25 View Cut - Barchart.com
Sector Update: Health Care - marketscreener.com
Baird Downgrades Iovance Biotherapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $20 - marketscreener.com
Iovance Biotherapeutics (IOVA) Price Target Cut Following Revised Revenue Outlook | IOVA Stock News - GuruFocus
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut - Zacks Investment Research
Iovance Biotherapeutics (IOVA) Price Target Lowered by HC Wainwright | IOVA Stock News - GuruFocus
Iovance Biotherapeutics (IOVA) Target Price Reduced but Buy Rating Maintained | IOVA Stock News - GuruFocus
Iovance Biotherapeutics: Q1 Earnings Snapshot - New Haven Register
Iovance Biotherapeutics Inc (IOVA) Q1 2025 Earnings Call Highlig - GuruFocus
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025 - GlobeNewswire
Iovance Biotherapeutics Q1 Loss Narrows, Revenue Rises - marketscreener.com
Iovance Biotherapeutics Reports Q1 2025 Financial Results - TipRanks
Iovance Biotherapeutics Inc (IOVA) Q1 2025 Earnings Call Highlights: Strong Revenue from Antagy ... By GuruFocus - Investing.com Canada
Iovance Biotherapeutics Inc (IOVA) Q1 2025 Earnings Call Highlights: Strong Revenue from Antagy ... - Yahoo Finance
Iovance Biotherapeutics Stock Is Crashing. And Here's Why Things Could Get Even Worse This Year. - AOL.com
Iovance Biotherapeutics Inc (IOVA) Q1 2025 Earnings Call Highlights: Strong Revenue from Antagy Launch Amid Manufacturing Challenges - GuruFocus
Decoding Iovance Biotherapeutics Inc (IOVA): A Strategic SWOT Insight - GuruFocus
(IOVA) Technical Data - news.stocktradersdaily.com
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):